Invasive Malignant Neoplasm — Trials

Invasive Malignant Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

1,820 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 604
Recruiting: 302
Ph III recruiting: 36
Growth YoY: +27.2%
Industry share: 19%
Top sponsor: National Cancer Institute (NCI)
Termination share: 37.1%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (283)

clinicaltrialsPublishedShowing 101–150 of 688 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07225270	Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy(RAINFOL-04)	recruiting	Phase 3	544	GenmabINDUSTRY	3	Sep 9, 2026	clinicaltrials
NCT07604766	An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China(RAINFOL-02)	recruiting	Phase 3	82	Genmab